Skip to content

A STUDY TO EVALUATE THE ROLE OF PROPHYLACTIC OCTREOTIDE IN PREVENTING ERCP INDUCED PANCREATITIS

A PROSPECTIVE RANDOMISED CONTROL TRIAL TO EVALUATE THE ROLE OF PROPHYLACTIC OCTREOTIDE IN PREVENTING ERCP INDUCED PANCREATITIS

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/10/007335
Enrollment
113
Registered
2016-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PATIENTS UNDERGOING ERCP PROCEDURE

Interventions

Intervention1: OCTREOTIDE: 3 doses of 100 micrograms will be given 12 hours, 6 hours and 45 minutes before the procedure. after the procedure, 100 microgram dose will be given after 6 hours and 12 hou

Sponsors

SETH GS MEDICAL COLLEGE AND KEM HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. WILLING TO PARTICIPATE IN THE STUDY 2. UNDERGOING ERCP FOR A VALID INDICATION 3. FOLOOWING UP WITH POST ERCP EVALUATION FOR DIAGNOSING PANCREATITIS

Exclusion criteria

Exclusion criteria: 1. PREGNANCY AND LACTATION 2. CHRONIC RENAL FAILURE 3. ACUTE MYOCARDIAL INFARCTION DURING THE LAST 3 MONTHS BEFORE PROCEDURE 4. HIV POSITIVE OR ANY OTHER IMMUNO-COMPROMISED STATE 5. PLANNED BILIARY STENT REMOVAL OR EXCHANGE 6. HISTORY OF ALCOHOL OR OTHER DRUG ABUSE 7.RECENT USE OF NARCOTIC ANALGESIC OR ANTICHOLINERGIC MEDICATION 8. HISTORY OF CHRONIC PANCREATITIS OR OTHER DISEASE KNOWN TO EFFECT PANCREATIC SECRETION (VAGOTOMY, GASTRECTOMY, INFLAMMATION) 9. REFUSAL TO PARTICIPATE 10. PATIENTS WITH PREVIOUS HISTORY OF ERCP INDUCED PANCREATITIS

Design outcomes

Primary

MeasureTime frame
% WITH ERCP INDUCED PANCREATITIS ACCORDING TO THE MODIFIED ATLANTA CLASSIFICATIONTimepoint: 48 HOURS THOUGH . The length of hospital stay will be decided by the treating unit under which the patient is admitted. In case, the patient is discharged before 48 hours, he or she will be followed on a telephonic interview basis.

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactANUJ SHARMA

SETH GS MEDICAL COLLEGE AND KEM HOSPITAL

anuj9863@gmail.com7303907379

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026